Advertisement

Topics

Medivir enrols first patient in combination trial for refractory solid tumours

19:00 EDT 20 Aug 2017 | Net Resources International

Swedish pharmaceutical company Medivir has started patient enrolment in a Phase I/II clinical trial of its product candidate birinapant in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) for treatment-refractory solid tumours.

Original Article: Medivir enrols first patient in combination trial for refractory solid tumours

NEXT ARTICLE

More From BioPortfolio on "Medivir enrols first patient in combination trial for refractory solid tumours"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...